Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IONS Ionis Pharmaceuticals, Inc

美国独立日休市 07-02 16:00:00 EDT

81.80

+2.61

+3.30%

盘后81.80

+0.000.00%

19:53 EDT

最高81.99	最低79.11	成交量230.19万
今开79.53	昨收79.19	日振幅3.64%
总市值135.13亿	流通市值134.15亿	总股本1.65亿
成交额1.86亿	换手率1.40%	流通股本1.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IONS","market":"US","secType":"STK","nameCN":"Ionis Pharmaceuticals, Inc","latestPrice":81.8,"timestamp":1783022400000,"preClose":79.19,"halted":0,"volume":2301899,"hourTrading":{"tag":"盘后","latestPrice":81.8,"preClose":81.8,"latestTime":"19:53 EDT","volume":67266,"amount":5502338.87,"timestamp":1783036384984,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0329587069074378,"floatShares":164000000,"shares":165192011,"eps":-2.027038,"marketStatus":"美国独立日休市","change":2.61,"latestTime":"07-02 16:00:00 EDT","open":79.53,"high":81.99,"low":79.11,"amount":186219071.33998,"amplitude":0.036368,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.027038,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":79.19,"preHourTrading":{"tag":"盘前","latestPrice":80.4,"preClose":79.19,"latestTime":"08:56 EDT","volume":49,"amount":3929.6098799999995,"timestamp":1782996981196,"change":1.21,"changeRate":0.01528,"amplitude":0.005051},"postHourTrading":{"tag":"盘后","latestPrice":81.8,"preClose":81.8,"latestTime":"19:53 EDT","volume":67266,"amount":5502338.87,"timestamp":1783036384984,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8825494452035406,"impliedVol":0.445,"impliedVolPercentile":0.506},"requestUrl":"/m/hq/s/IONS","defaultTab":"news","newsList":[{"id":"1102650612","title":"异动解读｜Ionis制药盘中上涨5.32%，Zilganersen全球商业化布局加速落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1102650612","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102650612?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:30","pubTimestamp":1782484257,"startTime":"0","endTime":"0","summary":"消息面上，公司宣布将亚历山大病在研药物Zilganersen的美国以外全球权益授权给Recordati，获得3000万美元预付款及最高达中20%区间的年净销售额里程碑付款和特许权使用费，同时保留美国市场独立商业化权利。该药此前在关键性研究中达到主要终点，50mg剂量在5岁及以上患者中展现出具统计学意义的步速稳定效果，并获得FDA优先审评资格。此次授权协议标志着公司在罕见病领域的商业化路径进一步明确，美国独立上市叠加海外合作模式有望最大化药物商业价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137969890","title":"艾奥尼斯制药计划独立在美国推出Zilganersen；FDA设定PDUFA日期为9月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=1137969890","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137969890?lang=zh_cn&edition=full","pubTime":"2026-06-25 15:02","pubTimestamp":1782370975,"startTime":"0","endTime":"0","summary":"艾奥尼斯制药公司宣布，计划独立在美国市场推出其药物Zilganersen。与此同时，美国食品药品监督管理局已将该药物的处方药使用者付费法案目标审评日期设定在9月22日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178831274","title":"Ionis与Recordati就亚历山大病药物Zilganersen达成美国以外全球授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1178831274","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178831274?lang=zh_cn&edition=full","pubTime":"2026-06-25 15:00","pubTimestamp":1782370818,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals宣布与Recordati公司就治疗亚历山大病的在研药物Zilganersen达成授权协议，该协议覆盖美国以外的所有国家和地区。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195534514","title":"Tryngolza®（奥莱扎森）获FDA批准，成为首个且唯一用于降低严重高甘油三酯血症患者甘油三酯水平及急性胰腺炎风险的疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1195534514","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195534514?lang=zh_cn&edition=full","pubTime":"2026-06-25 02:37","pubTimestamp":1782326235,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准Tryngolza®（奥莱扎森）上市，该药物成为首个且唯一获批用于降低严重高甘油三酯血症患者甘油三酯水平及急性胰腺炎风险的疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196480472","title":"FDA批准首款可降低成人严重高甘油三酯血症患者急性胰腺炎风险的治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1196480472","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196480472?lang=zh_cn&edition=full","pubTime":"2026-06-25 00:36","pubTimestamp":1782318972,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准首款经证实能够降低患有严重高甘油三酯血症的成人患者发生急性胰腺炎风险的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635805712","title":"Ionis(IONS)及合作伙伴Biogen共同宣布：diranersen相关研究取得具里程碑意义的成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2635805712","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635805712?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:54","pubTimestamp":1778759683,"startTime":"0","endTime":"0","summary":"金吾财讯 | Ionis(IONS)及其合作伙伴渤健(Biogen)共同宣布，用于治疗早期阿尔茨海默病(AD)的在研反义寡核苷酸(ASO)疗法diranersen(BIIB080)在II期CELIA研究中取得了具有里程碑意义的顶线结果。该研究首次证明，靶向Tau蛋白的疗法在减少病理蛋白堆积的同时，能显著改善患者的认知功能。基于此次研究中展现的生物标志物与疗效的强关联性，渤健已明确表示，计划将diranersen推进至注册开发阶段(即启动III期临床试验)。此前，美国FDA已于2025年授予该药“快速通道”认定。截至发稿，Ionis盘前走强，最新报81.88美元，上涨5.52%。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300446","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128412252","title":"合作伙伴渤健公布Diranersen (Biib080) II期Celia研究顶线结果：首项研究显示早期阿尔茨海默病患者tau病理减少及认知获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1128412252","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128412252?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:07","pubTimestamp":1778756850,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals的合作伙伴渤健公司近日公布了其候选药物DiranersenII期Celia研究的顶线结果。这项研究标志着在早期阿尔茨海默病治疗领域取得了一项重要进展，成为首项在患者中同时显示出减少tau病理蛋白沉积和带来认知益处的临床研究。该研究结果对于针对tau蛋白这一阿尔茨海默病核心病理标志物的疗法开发具有积极的指示意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138325383","title":"Ionis制药Q1营收2.46亿美元 大幅超越IBES预估1.956亿美元（修正版）","url":"https://stock-news.laohu8.com/highlight/detail?id=1138325383","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138325383?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:13","pubTimestamp":1777461182,"startTime":"0","endTime":"0","summary":"生物技术公司Ionis Pharmaceuticals最新公布的季度业绩表现亮眼，其第一季度营收达到2.46亿美元，远超市场预期。这一数字显著高于IBES机构此前作出的1.956亿美元预估，凸显出公司在创新疗法领域的强劲增长动能。\n财务数据显示，本季度营收同比实现显著提升，反映出核心产品商业化进程的加速。分析师指出，超额完成的营收业绩可能得益于罕见病药物销售的持续放量，以及合作伙伴里程碑款项的确认。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107981154","title":"Ionis制药公司大幅收窄2026年非GAAP运营亏损预期至4.25-4.75亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107981154","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107981154?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:12","pubTimestamp":1777461138,"startTime":"0","endTime":"0","summary":"生物技术企业Ionis Pharmaceuticals近日宣布调整财务指引，将2026年度非GAAP运营亏损预期区间从原先的5-5.5亿美元显著收窄至4.25-4.75亿美元。这一调整反映出公司在成本控制与运营效率方面的持续优化。\n此次指引修正凸显了Ionis在推进神经疾病和心血管疾病创新疗法研发的同时，对财务纪律的重视。亏损预期的降低可能源于研发管线进展带来的合作伙伴付款增加，以及运营支出管理的精细化措施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180560360","title":"财报前瞻｜Ionis Pharmaceuticals, Inc营收预计增56.17%，机构偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1180560360","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180560360?lang=zh_cn&edition=full","pubTime":"2026-04-22 13:22","pubTimestamp":1776835323,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc将于2026年04月29日美股盘前发布新季度财报，市场关注营收加速与亏损收窄节奏。市场一致预期本季度Ionis Pharmaceuticals, Inc营收为美元1.96亿，同比增长56.17%；调整后每股收益为-0.92美元，同比改善17.97%；息税前利润为-美元1.52亿，同比改善13.52%。从近期机构动态看，覆盖Ionis Pharmaceuticals, Inc的卖方以看多观点为主，核心依据在于业绩弹性与管线价值的双重支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Ionis Pharmaceuticals, Inc营收预计增56.17%，机构偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170375958","title":"Ionis制药Zilganersen 50毫克达主要终点 61周时≥5岁患者步速趋稳","url":"https://stock-news.laohu8.com/highlight/detail?id=1170375958","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170375958?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:07","pubTimestamp":1776769656,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals宣布，其研发的Zilganersen 50毫克在临床试验中成功达到主要研究终点。数据显示，在治疗第61周时，该药物能够有效稳定年龄在5岁及以上患者的步态速度。\n这一积极结果标志着Zilganersen在针对特定患者群体的治疗中展现出显著临床价值。步速稳定性作为关键运动功能指标，其改善意味着患者日常生活质量可能获得实质性提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105938867","title":"Ionis制药Zilganersen获FDA优先审评资格 PDUFA日期定为2026年9月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=1105938867","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105938867?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:06","pubTimestamp":1776769576,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc. 宣布其研发药物Zilganersen已获得美国食品药品监督管理局（FDA）的优先审评资格。该机构已将处方药用户付费法案（PDUFA）目标日期确定为2026年9月22日，标志着新药审评进程进入关键阶段。\n优先审评资格通常授予那些在治疗严重疾病方面可能提供显著进展的药物，此举将标准审评周期从10个月缩短至6个月。Zilganersen此次获得的审评资格，预示着该药物在解决未满足医疗需求方面展现出重要潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118668322","title":"Ionis制药公司关键次要终点结果一致显示Zilganersen优于对照组","url":"https://stock-news.laohu8.com/highlight/detail?id=1118668322","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118668322?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:05","pubTimestamp":1776769502,"startTime":"0","endTime":"0","summary":"Ionis制药公司公布的最新临床数据显示，其研究性药物Zilganersen在关键次要终点方面的表现持续优于对照组。这一结果进一步支持了该药物的潜在疗效，为后续研发提供了积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158180966","title":"Ionis制药宣布亚历山大病新药Zilganersen获FDA优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1158180966","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158180966?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:00","pubTimestamp":1774263619,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc. 近日宣布，其针对亚历山大病（AxD）研发的新药Zilganersen的新药申请（NDA）已获得美国食品药品监督管理局（FDA）的优先审评资格。这一重要进展意味着该药物的审评周期将有望缩短，为患有此种罕见神经系统疾病的患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189414337","title":"Ionis制药公司获FDA设定处方药用户费用法案目标行动日期为2026年6月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=1189414337","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189414337?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:03","pubTimestamp":1772107408,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已为Ionis制药公司（Ionis Pharmaceuticals, Inc）设定了一项关键监管节点——根据处方药用户费用法案（Pdufa），其目标行动日期定为2026年6月30日。\n这一日期标志着FDA完成对该公司相关药物申请审查的最终期限。该时间表的确定，为Ionis制药的研发进程提供了明确的监管时间框架，也预示着其新药审批流程进入倒计时阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164552946","title":"异动解读 | 预测2026年收入低于预期，Ionis Pharmaceuticals盘前大跌9.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164552946","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164552946?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:40","pubTimestamp":1772023241,"startTime":"0","endTime":"0","summary":"生物制药公司Ionis Pharmaceuticals  今日盘前股价大幅下跌9.54%，引起了市场的广泛关注。消息面上，该公司发布了最新的财务预测，预计2026年收入将在8亿至8.25亿美元之间，这一数字低于华尔街分析师平均预期的9.02亿美元。市场分析认为，对未来收入增长的保守预期是导致投资者信心受挫、股价在盘前交易时段承压下跌的主要原因。公司旗下遗传疾病药物Tryngolza在第四季度销售额达到5000万美元，环比增长56%，显示出良好的产品势头，但未能抵消市场对远期财务表现的担忧。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173104180","title":"财报前瞻｜Ionis Pharmaceuticals, Inc本季度营收预计增13.44%，欧洲获批与里程碑进度牵动预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1173104180","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173104180?lang=zh_cn&edition=full","pubTime":"2026-02-18 10:47","pubTimestamp":1771382875,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc将于2026年02月25日发布最新季度财报，市场关注商业板块增速、管线里程碑兑现与费用节奏的平衡。市场一致预期本季度Ionis Pharmaceuticals, Inc营收预计为1.56亿美元，同比增加13.44%；调整后每股收益预计为-1.32美元，同比下降17.63%；息税前利润预计为-2.10亿美元，同比下降19.11%；公司上季度并未在公开口径给出明确的季度营收或EPS指引。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Ionis Pharmaceuticals, Inc本季度营收预计增13.44%，欧洲获批与里程碑进度牵动预期","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191518855","title":"Ionis Pharmaceuticals, Inc 有望获得1500万美元里程碑付款及高达30%的净销售额分层特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1191518855","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191518855?lang=zh_cn&edition=full","pubTime":"2026-01-21 20:04","pubTimestamp":1768997079,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc 近日迎来重大利好消息。根据最新合作协议条款，该公司已具备资格获取一笔高达1500万美元的里程碑付款。更值得关注的是，其特许权使用费结构将采用分层模式，最高可达产品净销售额的30%。这一商业安排凸显了Ionis Pharmaceuticals核心产品的市场潜力。对于Ionis Pharmaceuticals而言，这笔潜在收益将为其研发管线注入新的资金支持，同时强化公司在罕见病和精准医疗领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145314898","title":"渤健公司获欧盟委员会批准Spiranza®高剂量方案用于脊髓性肌萎缩症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1145314898","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145314898?lang=zh_cn&edition=full","pubTime":"2026-01-13 00:11","pubTimestamp":1768234293,"startTime":"0","endTime":"0","summary":"欧盟委员会已正式批准渤健公司针对脊髓性肌萎缩症的Spiranza®（Nusinersen）高剂量治疗方案。这一监管里程碑标志着该疗法在欧盟市场获得重要拓展，为患者群体提供更具灵活性的用药选择。\n此次获批的高剂量方案将进一步提升药物在临床实践中的应用价值，凸显渤健公司在神经科学治疗领域持续创新的战略布局。监管机构的认可也为该疗法在更广泛患者群体中的使用铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","IE00B894F039.SGD","LU0889565916.HKD","BK4533","BK4139","IE00B19Z9Z06.USD","BK4585","BK4532","LU0234570918.USD","LU0109394709.USD","BIIB","LU0320765992.SGD","BK4588","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137439537","title":"Ionis合作伙伴葛兰素史克公布Bepirovirsen三期研究B-Well 1和B-Well 2积极顶线结果 该药物有望成为慢性乙肝首创疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1137439537","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137439537?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:18","pubTimestamp":1767770330,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc的合作伙伴葛兰素史克宣布，其针对慢性乙型肝炎的潜在首创药物Bepirovirsen，在三期临床研究B-Well 1和B-Well 2中取得了积极的顶线结果。这项关键进展标志着该疗法在追求功能性治愈慢性乙肝的道路上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ionis.com","stockEarnings":[{"period":"1week","weight":0.0442},{"period":"1month","weight":0.121},{"period":"3month","weight":0.0937},{"period":"6month","weight":0.0267},{"period":"1year","weight":0.8766},{"period":"ytd","weight":0.034}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"伊奥尼斯制药公司于1989年在加利福尼亚州注册成立，并于1991年1月将公司注册州变更为特拉华州。该公司花了三十年时间开拓RNA靶向药物，并已发展成为一家完全整合的商业阶段生物技术公司，拥有七种已上市药物，并拥有横跨神经病学、心脏代谢疾病和其他患者高需求领域的强大管道。它继续通过独立和合作开发推进下一代RNA靶向技术，为患有严重疾病的患者提供创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":-0.020204},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.015383},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.032273},{"month":4,"riseRate":0.363636,"avgChangeRate":0.01605},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.042937},{"month":6,"riseRate":0.818182,"avgChangeRate":0.057374},{"month":7,"riseRate":0.818182,"avgChangeRate":0.04048},{"month":8,"riseRate":0.5,"avgChangeRate":0.012224},{"month":9,"riseRate":0.5,"avgChangeRate":0.051342},{"month":10,"riseRate":0.2,"avgChangeRate":-0.026479},{"month":11,"riseRate":0.6,"avgChangeRate":0.097251},{"month":12,"riseRate":0.4,"avgChangeRate":0.002194}],"exchange":"NASDAQ","name":"Ionis Pharmaceuticals, Inc","nameEN":"Ionis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ionis Pharmaceuticals, Inc,IONS,Ionis Pharmaceuticals, Inc股票,Ionis Pharmaceuticals, Inc股票老虎,Ionis Pharmaceuticals, Inc股票老虎国际,Ionis Pharmaceuticals, Inc行情,Ionis Pharmaceuticals, Inc股票行情,Ionis Pharmaceuticals, Inc股价,Ionis Pharmaceuticals, Inc股市,Ionis Pharmaceuticals, Inc股票价格,Ionis Pharmaceuticals, Inc股票交易,Ionis Pharmaceuticals, Inc股票购买,Ionis Pharmaceuticals, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}